To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

Recruiting

Phase 3

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor ComplicationsTo Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

Sponsor:

Cerevance

Code:

NCT06553027

Conditions

Parkinson Disease

Eligibility Criteria

Sex: All

Age: 30+

Healthy Volunteers: Not accepted

Interventions

CVN424 75 mg

CVN424 150 mg

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-29. This information was provided to ClinicalTrials.gov by Cerevance on 2025-03-25.